REQUEST A DEMO
Total
USD $0.00
Search more companies

Substipharm Biologics Limited (Thailand)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Substipharm Biologics Limited Profile Updated: August 21, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

Substipharm Biologics Limited is an enterprise in Thailand, with the main office in Bangkok , Special Governed District of. It operates in the Pharmaceutical Preparation Manufacturing industry. The enterprise was incorporated on September 08, 2026. It currently has a total number of 100 (estimated) employees. In its most recent financial highlights, the company reported a net sales revenue increase of 529.34% in 2025. During that time, Substipharm Biologics Limited’s total assets grew by 1313.07%.

Headquarters
944 Rama Iv Road
Bangkok , Special Governed District of; Central Thailand; Postal Code: 10330

Contact Details: Purchase the Substipharm Biologics Limited report to view the information.

Basic Information
Total Employees:
Purchase the Substipharm Biologics Limited report to view the information.
Financial Auditors:
Purchase the Substipharm Biologics Limited report to view the information.
Incorporation Date:
September 08, 2026
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Substipharm Biologics Limited report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency THB. Absolute financial data is included in the purchased report.
Net sales revenue
529.34%
Total Operating Revenue
523.72%
Operating Profit
N/A
Net Profit/Loss for the Period
N/A
Total Assets
1313.07%
Total Equity
486.77%
Operating Profit Margin
N/A
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Debt / Equity
245.44%
Quick Ratio
0.63%
Cash Ratio
-0.7%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?